As vaccination campaigns are in full swing in critical markets, the perceived slow pace of vaccine adoption in several countries is in line with our expectations for overall vaccine access in mid-2021. This is mainly due to high logistical hurdles, unrealistic expectations of targets and limited supply of vaccines. At the country level, the adoption of immunization also depends on the country`s willingness to participate in direct investment and advance purchase agreements (APAs), as well as its ability to pay for doses. Vaccine prices are a key part of the equation; and while price levels are often not disclosed, APAs – which are tracked in our weekly report – provide a useful estimate in terms of future vaccine prices. „I welcome today`s agreements with Sinopharm and Sinovac, which will provide doses immediately to COVAX participants,” said Dr. Seth Berkley, CEO of Gavi. „This is another example of Gavi`s active portfolio management strategy to ensure the Facility has options in the face of constraints such as delivery delays. Thanks to this agreement and the fact that these vaccines have already been received from the WHO Emergency Use List, we can immediately start delivering doses to countries. Sinopharm`s APA enables Q3 supply, with Gavi committing to purchase 60 million doses on behalf of the COVAX facility, which will be available from July to October 2021. In addition, Gavi has the opportunity to acquire an additional 60 million doses in Q4 2021 and an additional 50 million doses in the first half of 2022, if necessary. This represents a potential total dose of 170 million doses of the Sinopharm vaccine that could be made available to the Facility`s self-funded participants as well as participants supported by Gavi`s Advance Market Commitment (AMC) COVAX. In this role, Gavi hosts the COVAX Facility OFFICE to coordinate the operation and governance of the mechanism as a whole, maintains financial and legal relationships with 193 facility participants, and manages the COVAX Facility Deals portfolio: negotiating pre-purchase agreements with manufacturers of promising vaccine candidates to obtain doses on behalf of all Participants in the CoVAX Facility.

Gavi also coordinates the design, operationalization and fundraising for the Gavi COVAX AMC, the mechanism that enables 92 low-income economies to access donor-funded vaccine doses. As part of this work, Gavi provides funding and oversight for UNICEF`s procurement and delivery of vaccines to all CMA participants – by operationalising pre-procurement agreements between Gavi and manufacturers – as well as support for partners` and governments` work on preparedness and delivery. This includes tailor-made support to governments, UNICEF, WHO and other partners for cold chain equipment, technical assistance, syringes, vehicles and other aspects of the highly complex logistics operation for delivery. Gavi is also co-creator, raising funds and supporting the operationalisation of the CMA`s no-fault compensation mechanism and the COVAX humanitarian buffer. Gavi and COVAX partners will now act quickly to ensure that all the critical elements required before the cans can be shipped, including the official allocation through the Facility, UNICEF and PAHO supply agreements, are in place. Gavi`s portfolio of the COVAX facility currently includes agreements for 11 vaccines and vaccine candidates – AstraZeneca/Oxford, Clover, Johnson & Johnson, Moderna, Novavax, Pfizer-BioNTech, Sanofi/GSK, SII-Covishield, SII-Covovax, Sinopharm and Sinovac – providing participants with access to a variety of vaccines suitable for use in different contexts and environments that mitigate the risk of R&D failures. the offer. Geneva, 12. July 2021 – Gavi, the Vaccine Alliance, today announced the signing of pre-purchase agreements (APAs) with Sinopharm for its inactivated viral vaccine „BBIBP-CorV” against COVID-19 and with Sinovac for its inactivated viral vaccine against COVID-19, „CoronaVac”.

The agreements, reached at a time when the delta variant poses an increasing risk to healthcare systems, will begin by immediately providing 110 million doses with options for additional doses to participants at the COVAX facility. . Approvals in major pharmaceutical markets (Australia, Canada, EU, United States). .